Back to Atlas
APotentially durableStandard research/education caution
CMP-0145
Investigational
Trevogrumab (Trevogumrab)
Ergogenic / Myostatin
Skeletal muscle growth or preservation through myostatin blockade
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Monoclonal antibody
- Primary mechanism
- Myostatin/GDF8 neutralization
- Primary market use
- Muscle preservation / sarcopenia / obesity combination
Pharmacology
- Molecular weight (Da)
- ~150,000
- Oral bioavailability
- N/A
- Half-life
- ~2-4 wk
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical
- Clinical status
- Investigational
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
User spelling Trevogumrab retained as alias; canonical spelling Trevogrumab